Back to Search
Start Over
SEOM-GEINO clinical guidelines for grade 2 gliomas (2023).
- Source :
-
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Nov; Vol. 26 (11), pp. 2856-2865. Date of Electronic Publication: 2024 Apr 25. - Publication Year :
- 2024
-
Abstract
- The 2021 World Health Organization (WHO) classification has updated the definition of grade 2 gliomas and the presence of isocitrate dehydrogenase (IDH) mutation has been deemed the cornerstone of diagnosis. Though slow-growing and having a low proliferative index, grade 2 gliomas are incurable by surgery and complementary treatments are vital to improving prognosis. This guideline provides recommendations on the multidisciplinary treatment of grade 2 astrocytomas and oligodendrogliomas based on the best evidence available.<br /> (© 2024. The Author(s).)
- Subjects :
- Humans
Isocitrate Dehydrogenase genetics
Astrocytoma therapy
Astrocytoma pathology
Astrocytoma genetics
Oligodendroglioma therapy
Oligodendroglioma genetics
Oligodendroglioma pathology
Societies, Medical
Glioma therapy
Glioma genetics
Glioma pathology
Brain Neoplasms therapy
Brain Neoplasms genetics
Brain Neoplasms pathology
Neoplasm Grading
Subjects
Details
- Language :
- English
- ISSN :
- 1699-3055
- Volume :
- 26
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
- Publication Type :
- Academic Journal
- Accession number :
- 38662171
- Full Text :
- https://doi.org/10.1007/s12094-024-03456-x